Phase I study of divided-dose vinblastine in advanced malignancy

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Advanced malignancy treatment often involves complex chemotherapy regimens.
• Vinblastine is a vinca alkaloid used in various cancer therapies.
• Evaluating novel dosing schedules is crucial for optimizing treatment efficacy and tolerability.

Purpose of the Study:

• To assess the safety and efficacy of a divided-dose intravenous bolus vinblastine regimen.
• To evaluate the toxicity profile of this vinblastine dosing strategy in heavily pretreated patients.
• To compare serum vinblastine levels achieved with this regimen to those from standard continuous infusion protocols.

Main Methods:

• Thirty-one patients with advanced malignancy were enrolled.
• Vinblastine was administered as an intravenous bolus at 0 and 48 hours within a 21-day cycle.
• Toxicity, including leukopenia and neuropathy, and patient response were monitored.

Main Results:

• The divided-dose vinblastine regimen was found to be acceptable in terms of toxicity for heavily pretreated patients.
• Leukopenia and neuropathy were identified as the primary dose-limiting toxic effects.
• One patient with breast cancer and one with ovarian cancer demonstrated a response to the treatment.
• Serum vinblastine concentrations approximated those seen with a standard 5-day continuous infusion.

Conclusions:

• Divided-dose intravenous bolus vinblastine can be administered with acceptable toxicity in patients with advanced malignancy.
• This dosing schedule may represent an alternative administration route for vinblastine therapy.
• Further investigation into this regimen's clinical utility is warranted.